EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study

Liangshun You, Yi Liu, Wenyuan Mai, Wanzhuo Xie, De Zhou, Liping Mao, Lili Chen, Xinping Zhou, Liya Ma, Xiaolong Zheng, Juying Wei, Yinjun Lou und 4 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.113979 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Liangshun You und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of Ch…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Leukopenia, Sulfonamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteLeukopeniaSulfonamidesHumansCytarabineAzacitidineBridged Bicyclo Compounds, HeterocyclicPathologic Complete ResponseAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

AzatidineCytarabineRelapsed and Refractory AMLVenetoclax

Substanzen

CytarabineAzacitidinevenetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China; Zhejiang Provincial Clinical Research Center for Hematologic Dise…
  • The First People's Hospital of Taizhou, Huangyan District, Zhejiang China.

Zitieren

APA

You, L., Liu, Y., Mai, W., Xie, W., Zhou, Mao, L., Chen, L., Zhou, X., Ma, L., Zheng, X., Wei, J., Lou, Y., Ye, X., Tong, H., Jin, J., & Meng, H. (2024). Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.113979

Vancouver

You L, Liu Y, Mai W, Xie W, Zhou, Mao L, et al. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.113979

BibTeX
@article{You2024,
  author = {You, Liangshun and Liu, Yi and Mai, Wenyuan and Xie, Wanzhuo and Zhou, De and Mao, Liping and Chen, Lili and Zhou, Xinping and Ma, Liya and Zheng, Xiaolong and Wei, Juying and Lou, Yinjun and Ye, Xingnong and Tong, Hongyan and Jin, Jie and Meng, Haitao},
  title = {Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.113979}
}
Kostenlos starten →